Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The unlikely partnership between LRRK2 and α‐synuclein in Parkinson's disease
Noémie Cresto, Gardier Camille, Francesco Gubinelli, et al.
European Journal of Neuroscience (2018) Vol. 49, Iss. 3, pp. 339-363
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

LRRK2 in Parkinson disease: challenges of clinical trials
Eduardo Tolosa, Miquel Vila, Christine Klein, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 2, pp. 97-107
Closed Access | Times Cited: 371
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Ahmad Elkouzi, Vinata Vedam‐Mai, Robert S. Eisinger, et al.
Nature Reviews Neurology (2019) Vol. 15, Iss. 4, pp. 204-223
Open Access | Times Cited: 252
Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 239
Mechanisms and roles of mitophagy in neurodegenerative diseases
Yan Wang, Na Liu, Bingwei Lu
CNS Neuroscience & Therapeutics (2019) Vol. 25, Iss. 7, pp. 859-875
Open Access | Times Cited: 189
Role of JAK/STAT in the Neuroinflammation and its Association with Neurological Disorders
Mayank Jain, Mukul Kumar Singh, Hari Shyam, et al.
Annals of Neurosciences (2021) Vol. 28, Iss. 3-4, pp. 191-200
Open Access | Times Cited: 98
Novel targeted therapies for Parkinson’s disease
Theodora Ntetsika, Paraskevi-Evita Papathoma, Ioanna Markaki
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 78
Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson’s Disease
Xinyu Hu, Jingwen Li, Xinyi Wang, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 396-396
Open Access | Times Cited: 28
In vivo self-assembled siRNAs within small extracellular vesicles attenuate LRRK2-induced neurodegeneration in Parkinson's disease models
Li Zhang, Penglu Chen, Tiantian Chen, et al.
Journal of Controlled Release (2025) Vol. 378, pp. 1139-1153
Open Access | Times Cited: 1
LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s
Rebecca L. Wallings, Mary K. Herrick, Malú G. Tansey
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 66
LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Changyoun Kim, A Beilina, Nathan Smith, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 565
Open Access | Times Cited: 62
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
Darren M. O’Hara, Grishma Pawar, Suneil K. Kalia, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 60
Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications
Rosie Bell, Michele Vendruscolo
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 33
Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment
Richard Smith, Hanna Hovren, Robert Bowser, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 4
Open Access | Times Cited: 5
Long-Term Outcomes of Genetic Parkinson’s Disease
Jan Aasly
Journal of Movement Disorders (2020) Vol. 13, Iss. 2, pp. 81-96
Open Access | Times Cited: 38
Leucine-rich repeat kinase 2 at a glance
Christiane Zhu, Susanne Herbst, Patrick A. Lewis
Journal of Cell Science (2023) Vol. 136, Iss. 17
Open Access | Times Cited: 9
Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out
Sarah MacIsaac, Thaiany Quevedo Melo, Yuting Zhang, et al.
Brain Communications (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 26
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Francesca Pischedda, Maria Daniela Cirnaru, Luisa Ponzoni, et al.
Brain (2021) Vol. 144, Iss. 5, pp. 1509-1525
Open Access | Times Cited: 23
Genes Implicated in Familial Parkinson’s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage
Rafael Franco, Rafael Rivas‐Santisteban, Gemma Navarro, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4643-4643
Open Access | Times Cited: 19
From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2
Andrea Mancini, Petra Mazzocchetti, Miriam Sciaccaluga, et al.
Frontiers in Cellular Neuroscience (2020) Vol. 14
Open Access | Times Cited: 18
Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
Alícia Garrido, Enrique Santamaría, Joaquín Fernández‐Irigoyen, et al.
Movement Disorders (2022) Vol. 37, Iss. 5, pp. 1004-1015
Open Access | Times Cited: 12
LRRK2 and Proteostasis in Parkinson’s Disease
María Dolores Pérez‐Carrión, Inmaculada Posadas, Javier Solera, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6808-6808
Open Access | Times Cited: 12
Total Glucosides of White Paeony Capsule ameliorates Parkinson's disease-like behavior in MPTP-induced mice model by regulating LRRK2/alpha-synuclein signaling
Hongyan Li, Deshui Liu, Libo Li, et al.
Journal of Ethnopharmacology (2023) Vol. 319, pp. 117319-117319
Closed Access | Times Cited: 6
The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo
Noémie Cresto, Marie‐Claude Gaillard, Camille Gardier, et al.
Neurobiology of Disease (2019) Vol. 134, pp. 104614-104614
Open Access | Times Cited: 18
LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Tiago F. Outeiro, Kirsten Harvey, Antonio Dominguez‐Meijide, et al.
Biochemical Society Transactions (2019) Vol. 47, Iss. 3, pp. 827-838
Open Access | Times Cited: 16
Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects
Philip Wing‐Lok Ho, Eunice Eun-Seo Chang, Chi-Ting Leung, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top